Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.
PMID: 16539393
2006
Journal of medicinal chemistry
Abstract: These compounds were also found to retain sensitivity against lamivudine-resistant HBV containing a single mutation (M204I) and double mutations (L180M/M204V).
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
Abstract: In conclusion, switching to ADV monotherapy after emergence of LAM-resistant rtM204 I/V is effective and safe in cirrhotic patients, even in those with hepatic decompensation.
Abstract: Switching to adefovir (ADV) monotherapy is effective in patients with lamivudine (LAM)-resistant hepatitis B virus (HBV) mutations (rtM204 I/V).
Abstract: The clinical, biochemical and virological responses were compared between ADV monotherapy in 18 cirrhotic patients and ADV add-on LAM therapy in 10 comparable cirrhotic patients with LAM-resistant rtM204 I/V.
Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor.
PMID: 16611347
2006
American journal of transplantation
Abstract: De novo HBV infection developed more than 3 years after LT with a lamivudine-resistant polymerase mutant containing the rtM204I and rtl180L/M mutations.
Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
Abstract: RFMP exploits differences in molecular masses between wild-type and variant bases of rtM204V/I following PCR amplification of HBV DNA with a lower limit of detection being 100 copies/mL.
Antiviral drug resistance: clinical consequences and molecular aspects.
Abstract: Changes in rtM204I and rtL180M viral loads were greater than that of the rtM204V, albeit statistically insignificant.
Abstract: Moreover, the greatest change in viral load was seen for rtM204I without hepatitis B e antigen (HBeAg).
Abstract: We conclude that the rtM204I may be more sensitive to ADV in vivo.
Abstract: We determined early viral changes (12 weeks) in YMDD mutants (rtM204I [YIDD sequence],
Mutations in surface and polymerase gene of chronic hepatitis B patients with coexisting HBsAg and anti-HBs.
PMID: 16830379
2006
World journal of gastroenterology
Abstract: Lamivudine (LMV)-selected mutations were found in three patients who developed anti-HBs, which occurred in amino acid positions (196, 198, 199) of the surface protein and in YMDD motif (M204I/V) of the polymerase protein simultaneously.
The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Abstract: Cumulative viral breakthrough rates at 3 years was 75.0% and 14.3% in patients who had the rtM204I mutant and wild-type virus at 3 months, respectively (P=0.002).
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
Abstract: Lamivudine-associated mutations (rtV173L, rtL180M, rtM204V/I) could be detected in 6 patients at baseline of TDF, but this obviously did not influence the response.
Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment.
PMID: 16981258
2006
World journal of gastroenterology
Abstract: Primer specific to rtM204I with an additional 3'-penultimate base mismatched to both the mutant and wild-type sequence was selected for YIDD detection.
HBV mutation literature information.
PMID: 
2006
Journal of medicinal chemistry
Browser Board
Co-occurred Entities
Filtrator
ViMRT